Article
Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database.
Carcinogenesis - 1 Dec 2002
Bykov Vladimir J N, Issaeva Natalia, Selivanova Galina, Wiman Klas G
Abstract excerpt
We recently identified PRIMA-1 as a low molecular weight compound that restores tumor suppressor function to mutant p53 proteins and has anti-tumor activity in vivo (1). Here we report the statistical analysis of the effect of PRIMA-1 on a panel of human tumor cell lines using information available in a database at the Developmental Therapeutics Program of the National Cancer Institute (NCI). We extracted growth...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.